Disc Medicine, Inc. (IRON)

On our desk, we are seeing intense debate following the Rosen Law Firm's shareholder investigation. The core concern is whether management adequately communicated the risks surrounding the prior FDA Complete Response Letter for bitopertin. While the stock trades at roughly $2.1 billion net of cash, the looming legal shadow makes near-term sentiment fragile despite the recent Type A meeting alignment.

From a clinical protocol standpoint, the Type A meeting with the FDA is a massive relief. Confirming that a successful Phase 3 APOLLO study can directly serve as the basis for the CRL response gives us a clean binary endpoint for Q4 2026. However, clinicians are watching Tanabe's dersimelagon closely, as it could outpace bitopertin to the EPP/XLP market and alter commercial positioning.

Hedging with Q4 put spreads has become a popular strategy on our trading floor. With the entire valuation hinging on the Q4 2026 APOLLO topline data, any negative surprise would completely derail the approval path and trigger severe downside, especially given that the previous accelerated approval path was already blocked by the FDA.

Looking at the broader pipeline outside of bitopertin, we are keeping a close eye on the RALLY-MF Phase 2 trial for selcodebart in myelofibrosis anemia and the RESTORE-PV Phase 2 study for DISC-3405, which expects initial data in Q3 2026. These secondary readouts provide crucial diversification away from the single-asset binary risk of bitopertin.

As a bio-analyst tracking the cash burn, seeing a net loss of US$59.53 million in Q2 2026 isn't shocking for a clinical-stage biotech, but it does amplify the stakes. Fortunately, with total cash reported at over $730 million against minimal debt, the company has enough runway to push through its upcoming catalysts without an immediate dilutive equity panic, provided clinical timelines hold.